Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide for Enterocutaneous Fistula
NCT02889393Phase 2Completed
- Start
- Jan 2019
- Primary completion
- Jul 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of teduglutide in enterocutaneous fistula (ECF) (2 arms). Primary endpoint: Change in Average 3-day Fistula Percent Volume at 8 weeks. Started Jan 2019; status: completed.
02
Drugs
teduglutide
03
Conditions
enterocutaneous fistula (ECF)
Beyond the preview
Go deeper on NCT02889393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02889393.